Anti-VEGF therapy in mRCC: differences between Asian and non-Asian patients

BACKGROUND: Several reports suggest that vascular endothelial growth factor (VEGF)-targeted therapy in metastatic renal cell carcinoma (mRCC) may be more toxic in Asian vs non-Asian populations. Comparative efficacy of these agents with respect to ethnicity is not well characterised. METHODS: A mult...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Y, Choueiri, T K, Lee, J-L, Tan, M-H, Rha, S Y, North, S A, Kollmannsberger, C K, McDermott, D F, Heng, D Y C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2014
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3960609/
https://www.ncbi.nlm.nih.gov/pubmed/24548864
http://dx.doi.org/10.1038/bjc.2014.28

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3960609/
https://www.ncbi.nlm.nih.gov/pubmed/24548864
http://dx.doi.org/10.1038/bjc.2014.28

Ejemplares similares